A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

被引：0
|
作者：
Cody J. Peer
Keith T. Schmidt
Jessica D. Kindrick
Joel R. Eisner
Victoria V. Brown
Edwina Baskin-Bey
Ravi Madan
William D. Figg
机构：
[1] National Cancer Institute,Clinical Pharmacology Program, CCR
[2] NIH,Genitourinary Malignancies Branch
[3] Innocrin Pharmaceuticals,undefined
[4] National Cancer Institute,undefined
[5] NIH,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Seviteronel CYP17 lyase; Population pharmacokinetics; Prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 770
页数：11
相关论文
共 50 条
  • [21] Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer
    Ang, Daniel
    Chan, Johan
    Ong, Whee Sze
    Tan, Hui Shan
    Ng, Quan Sing
    Yuen, John
    Chen, Kenneth
    Tay, Kae Jack
    Wong, Siew Wei
    Saad, Marniza
    Nagata, Masayoshi
    Horie, Shigeo
    Chansriwong, Phichai
    Ng, Chi-Fai
    Wong, Alvin
    Chua, Melvin L. K.
    Toh, Chee Keong
    Tan, Min-Han
    Lim, Tony
    Bhagat, Ali Asgar S.
    Kanesvaran, Ravindran
    JCO PRECISION ONCOLOGY, 2024, 8
  • [22] Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    George, Daniel J.
    Morgans, Alicia K.
    Constantinovici, Niculae
    Khan, Nasreen
    Khan, Javeed
    Chen, Guifang
    Hlebec, Vlasta
    Shore, Neal D.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [23] Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (SEVI), a selective CYP17 lyase and AR inhibitor.
    Speers, Corey Wayne
    Chandler, Benjamin
    Zhao, Shuang
    Liu, Meilan
    Wilder-Romans, Kari
    Olsen, Eric
    Nyati, Shyam
    Rae, James M.
    Hayes, Daniel F.
    Spratt, Daniel Eidelberg
    Wahl, Daniel Richard
    Feng, Felix Yi-Chung
    Pierce, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration-Resistant Prostate Cancer
    Liu, Yixian
    He, Yongji
    Qi, Xiaohui
    Li, Xinghai
    Zhou, Yi
    Chen, Yuanwei
    Wang, Zhenlei
    Zheng, Li
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (12): : 1291 - 1300
  • [25] Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
    Rehman, Yasser
    Rosenberg, Jonathan E.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 : 13 - 18
  • [26] Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor
    Tilki, Derya
    Schaeffer, Edward M.
    Evans, Christopher P.
    EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 499 - 505
  • [27] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Attard, Gerhardt
    Reid, Alison H. M.
    A'Hern, Roger
    Parker, Christopher
    Oommen, Nikhil Babu
    Folkerd, Elizabeth
    Messiou, Christina
    Molife, L. Rhoda
    Maier, Gal
    Thompson, Emilda
    Olmos, David
    Sinha, Rajesh
    Lee, Gloria
    Dowsett, Mitch
    Kaye, Stan B.
    Dearnaley, David
    Kheoh, Thian
    Molina, Arturo
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
  • [28] Androgen receptor (AR) aberrations in castration-resistant prostate cancer
    Waltering, Kati K.
    Urbanucci, Alfonso
    Visakorpi, Tapio
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 360 (1-2) : 38 - 43
  • [29] Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
    Feng, Qin
    He, Bin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [30] Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer
    Bedoya, Diego J.
    Mitsiades, Nicholas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (01) : 1 - 3
12345